Fibrodysplasia Ossificans Progressiva - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

GE Vernova's 9E gas turbine and generator will form part of the proposed 372 MW Songon combined-cycle power station near Abidjan, Côte d'Ivoire, which is targeting commercial operation in 2029.

GE Vernova secures Songon gas turbine order for 372 MW Côte d’Ivoire power project

CSTS Enterprises prepares PremierX's official debut at Pier 17 with Halloween weekend music event

CSTS brings PremierX to Pier 17 with Lil Xan and DJ Soda, but can one New York event become a global entertainment brand?

Andhra Pradesh local elections delayed after Supreme Court intervenes over nomination violence

Monster Energy stages immersive Call of Duty: Modern Warfare 4 launch at Cosm Los Angeles

Monster Energy takes Call of Duty beyond the screen, but can immersive gaming events turn fan loyalty into beverage sales?

Business News Today infographic showing FDA approval of Atebrioz for fibrodysplasia ossificans progressiva, highlighting an October 2026 US launch, an estimated 300 diagnosed US patients, key PROGRESS study results, and the Mirum-Incyte licensing economics.

Read More

Pharma Industry News

Mirum wins Atebrioz FDA approval after $16m Incyte licence in rare FOP market

Mirum Pharmaceuticals has secured FDA approval for Atebrioz in patients aged 12 and older with fibrodysplasia ossificans progressiva, only months after licensing zilurgisertib from Incyte for $16 million upfront plus milestones and royalties.

September 28, 2026

web analytics